Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

NCT04036461 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04036461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04036461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
August 26, 2019
Completion date
August 19, 2024
Enrollment
47 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma